Drug Information

Drug General Information
Drug ID
D09IMK
Former ID
DNC006569
Drug Name
Cbz-Ile-t-ButylGln-Ala-LeuVSMe
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528196]
Formula
C34H55N5O8S
Canonical SMILES
CCC(C)C(C(=O)NC(CCC(=O)NC(C)(C)C)C(=O)NC(C)C(=O)NC(CC(C<br />)C)C=CS(=O)(=O)C)NC(=O)OCC1=CC=CC=C1
InChI
1S/C34H55N5O8S/c1-10-23(4)29(38-33(44)47-21-25-14-12-11-13-15-25)32(43)37-27(16-17-28(40)39-34(6,7)8)31(42)35-24(5)30(41)36-26(20-22(2)3)18-19-48(9,45)46/h11-15,18-19,22-24,26-27,29H,10,16-17,20-21H2,1-9H3,(H,35,42)(H,36,41)(H,37,43)(H,38,44)(H,39,40)/b19-18+/t23-,24-,26+,27-,29-/m0/s1
InChIKey
YIFPZVMURBGBNU-NHVLHDLVSA-N
PubChem Compound ID
11621748
Target and Pathway
Target(s) Cathepsin S Target Info Inhibitor [528196]
KEGG Pathway Lysosome
Phagosome
Antigen processing and presentation
Tuberculosis
NetPath Pathway Leptin Signaling Pathway
IL2 Signaling Pathway
Reactome Endosomal/Vacuolar pathway
Degradation of the extracellular matrix
Trafficking and processing of endosomal TLR
Assembly of collagen fibrils and other multimeric structures
MHC class II antigen presentation
WikiPathways Class I MHC mediated antigen processing & presentation
Trafficking and processing of endosomal TLR
References
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.
Ref 528196J Med Chem. 2006 May 18;49(10):2953-68.Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and cellular properties of potent, selective proteasome inhibitors.